The long-acting C5 inhibitor, Ravulizumab, is effective and safe in adult patients with atypical hemolytic uremic syndrome naïve to complement inhibitor treatment.
暂无分享，去创建一个
N. Heyne | Y. Miyakawa | G. Ariceta | H. Haller | G. La Manna | Sung-Soo Yoon | M. Fischereder | Jin Seok Kim | D. Kavanagh | T. Kasimatis | Chiu-Ching Huang | E. Rondeau | S. Griffin | F. Provôt | E. Gutiérrez | S. Cataland | G. Arepally | M. Okumi | V. Dobronravov | Y. Luque | E. Wong | J. Menne | C. Garrouste | M. Le Quintrec | D. Oh | S. Boyer-Suavet | B. Seitz-Polski | S. Nagaraj | M. Cappuccilli | G. Favre | E. Swenson | Y. Delmas | G. Comai | N. Broeders | J. Morelle | T. Barbour | U. Schönermarck | F. Brown | L. Caroti | L. Cirami | P. Campbell | I-Ru Chen | M. Scully | G. Greenwood | Manuel Praga Terente | S. Babu | M. Vinogradova | Susan Huang | P. Chowdhury | S. Ortiz | T. Kirsanova | Guillaume Jeantet | É. Goffin | M. Vallée | N. Lietar | Guilia Antognoli | Anja Gaeckler | Iino Fumie | Anja Muhlfeld | N. Terrada | P. Rodríguez | I. Chen | Fiona C. Brown | Sonia Boyer-Suavet | Yahsou Delmas | S. Yoon